Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Arterra Bioscience S.p.A. is a biotechnology company that focuses on the research and development of innovative solutions derived from natural sources. The company specializes in developing eco-sustainable technologies that cater to various industries, including cosmetics, agriculture, and nutraceuticals. Arterra Bioscience leverages cutting-edge biotechnological processes to harness the potential of nature, creating high-value active ingredients that promote sustainability and environmental conservation. With a keen emphasis on protecting biodiversity, Arterra develops biotechnological formulations and products that are both effective and environmentally friendly. The company serves a diverse clientele ranging from major cosmetic companies seeking sustainable formulations to agricultural firms aiming for eco-friendly pest management solutions. Founded in Italy, Arterra Bioscience is acknowledged for its commitment to scientific research and the advancement of green technologies. The company's presence in the biotech sector marks it as a crucial player in addressing modern-day challenges through sustainable innovation. By prioritizing environmental sustainability and scientific integrity, Arterra Bioscience contributes to essential industry shifts towards more responsible and nature-focused practices.
Margins and capital returns are both well above average: 43.22% operating margin, ROIC at 16.52%. Consistent with durable pricing power, though that alone doesn't make it a buy.
Revenue up 12.7% YoY with margins expanding 8.0pp.
Insufficient data to identify specific risks. Treat any missing metrics as a data gap, not a clean bill of health.
Profitability & Returns
Revenue (TTM)
€5M
▲ +12.7% YoY
Net Income (TTM)
€2M
▲ +50.1% YoY
Op. Margin
43.22%
▲ +8.0pp YoY
ROIC
16.52%
▲ +6.4pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
€2M
▲ +285.3% YoY
Op. Cash Flow (TTM)
€2M
▲ +363.0% YoY
Net Debt
-€1M
Net Cash Position
Cash & Equiv.
€1M
3Y CAGR: +9.4%
3Y CAGR: +5.9%
Continue Research